Predisposition to Lung Adenocarcinoma in a Family Harboring the Germline V843I Mutation.
作者信息
Ohtsuka Kouki, Ohnishi Hiroaki, Fujiwara Masachika, Morii Takeshi, Matsushima Satsuki, Ogura Wataru, Yamasaki Satoko, Kishino Tomonori, Tanaka Ryota, Watanabe Takashi
机构信息
Kyorin University School of Medicine, Tokyo, Japan.
出版信息
JCO Precis Oncol. 2019 Jul 26;3. doi: 10.1200/PO.19.00104. eCollection 2019.
Abstract
摘要
相似文献
1
Predisposition to Lung Adenocarcinoma in a Family Harboring the Germline V843I Mutation.携带种系V843I突变的家族中患肺腺癌的易感性。
JCO Precis Oncol. 2019 Jul 26;3. doi: 10.1200/PO.19.00104. eCollection 2019.
2
Novel germline mutation: EGFR V843I in patient with multiple lung adenocarcinomas and family members with lung cancer.新型胚系突变：多发肺腺癌患者及肺癌家族成员中的EGFR V843I突变
Ann Thorac Surg. 2008 Apr;85(4):1430-2. doi: 10.1016/j.athoracsur.2007.10.012.
3
V843I, a lung cancer predisposing EGFR mutation, is responsible for resistance to EGFR tyrosine kinase inhibitors.V843I 是一种肺癌易感型 EGFR 突变，它导致对 EGFR 酪氨酸激酶抑制剂的耐药性。
J Thorac Oncol. 2014 Sep;9(9):1377-84. doi: 10.1097/JTO.0000000000000241.
4
A dramatic lung cancer course in a patient with a rare EGFR germline mutation exon 21 V843I: Is EGFR TKI resistance predictable?罕见 EGFR 胚系突变exon21 V843I 患者的戏剧性肺癌病程：EGFR TKI 耐药是否可预测？
Lung Cancer. 2013 Apr;80(1):81-4. doi: 10.1016/j.lungcan.2012.11.013. Epub 2013 Feb 4.
5
Familial lung adenocarcinoma caused by the EGFR V843I germ-line mutation.由EGFR V843I种系突变引起的家族性肺腺癌。
J Clin Oncol. 2011 Mar 10;29(8):e191-2. doi: 10.1200/JCO.2010.31.4492. Epub 2010 Dec 20.
6
EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer.中国肺癌患者中 EGFR 和 ERBB2 种系突变及其在癌症遗传易感性中的作用。
J Thorac Oncol. 2019 Apr;14(4):732-736. doi: 10.1016/j.jtho.2018.12.006. Epub 2019 Jan 2.
7
Inherited lung cancer syndromes targeting never smokers.针对从不吸烟者的遗传性肺癌综合征。
Transl Lung Cancer Res. 2018 Aug;7(4):498-504. doi: 10.21037/tlcr.2018.06.01.
8
Higher frequency but random distribution of EGFR mutation subtypes in familial lung cancer patients.家族性肺癌患者中表皮生长因子受体（EGFR）突变亚型的分布频率较高但呈随机分布。
Oncotarget. 2016 Aug 16;7(33):53299-53308. doi: 10.18632/oncotarget.10715.
9
Monitoring of cyclooxygenase-2 levels can predict EGFR mutations and the efficacy of EGFR-TKI in patients with lung adenocarcinoma.监测环氧化酶-2水平可预测肺腺癌患者的表皮生长因子受体（EGFR）突变情况及EGFR酪氨酸激酶抑制剂（EGFR-TKI）的疗效。
Int J Clin Exp Pathol. 2015 May 1;8(5):5577-83. eCollection 2015.
引用本文的文献
1
Clinical implications of the family history in patients with lung cancer: a systematic review of the literature and a new cross-sectional/prospective study design (FAHIC: lung).肺癌患者家族史的临床意义：文献系统综述及新的横断面/前瞻性研究设计（FAHIC：肺癌）
J Transl Med. 2024 Jul 31;22(1):714. doi: 10.1186/s12967-024-05538-4.
2
Lung cancer is also a hereditary disease.肺癌也是一种遗传性疾病。
Eur Respir Rev. 2021 Oct 20;30(162). doi: 10.1183/16000617.0045-2021. Print 2021 Dec 31.
3
Male Breast Cancer: Results of the Application of Multigene Panel Testing to an Italian Cohort of Patients.男性乳腺癌：多基因检测在意大利患者队列中的应用结果
Diagnostics (Basel). 2020 Apr 30;10(5):269. doi: 10.3390/diagnostics10050269.
本文引用的文献
1
Prognostic Effect of TP53 and PKD Co-Mutations in Patients with Resected Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma.TP53 与 PKD 共突变对表皮生长因子受体突变肺腺癌患者术后的预后影响
Ann Surg Oncol. 2019 Jun;26(6):1934-1941. doi: 10.1245/s10434-019-07254-6. Epub 2019 Feb 28.
2
Influence of Mutation on Survival in Patients With Advanced -Mutant Non-Small-Cell Lung Cancer.突变对晚期突变型非小细胞肺癌患者生存的影响。
JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00107. Epub 2018 Aug 31.
3
Genome analyses for the Tohoku Medical Megabank Project towards establishment of personalized healthcare.基因组分析助力东北医疗集团医疗大数据联盟建立个性化医疗体系
J Biochem. 2019 Feb 1;165(2):139-158. doi: 10.1093/jb/mvy096.
4
Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).TP53共突变对表皮生长因子受体（EGFR）突变的非小细胞肺癌（NSCLC）患者的预后和预测作用。
Lung Cancer. 2017 Sep;111:23-29. doi: 10.1016/j.lungcan.2017.06.014. Epub 2017 Jun 24.
5
Rare variant discovery by deep whole-genome sequencing of 1,070 Japanese individuals.通过对1070名日本个体进行全基因组深度测序发现罕见变异。
Nat Commun. 2015 Aug 21;6:8018. doi: 10.1038/ncomms9018.
6
V843I, a lung cancer predisposing EGFR mutation, is responsible for resistance to EGFR tyrosine kinase inhibitors.V843I 是一种肺癌易感型 EGFR 突变，它导致对 EGFR 酪氨酸激酶抑制剂的耐药性。
J Thorac Oncol. 2014 Sep;9(9):1377-84. doi: 10.1097/JTO.0000000000000241.
7
Novel germline mutation in the transmembrane domain of HER2 in familial lung adenocarcinomas.家族性肺腺癌中 HER2 跨膜结构域的新型种系突变。
J Natl Cancer Inst. 2014 Jan;106(1):djt338. doi: 10.1093/jnci/djt338. Epub 2013 Dec 7.
8
Germline mutations in driver oncogenes and inherited lung cancer risk independent of smoking history.驱动癌基因中的种系突变与独立于吸烟史的遗传性肺癌风险。
J Natl Cancer Inst. 2014 Jan;106(1):djt361. doi: 10.1093/jnci/djt361. Epub 2013 Dec 7.
9
A dramatic lung cancer course in a patient with a rare EGFR germline mutation exon 21 V843I: Is EGFR TKI resistance predictable?罕见 EGFR 胚系突变exon21 V843I 患者的戏剧性肺癌病程：EGFR TKI 耐药是否可预测？
Lung Cancer. 2013 Apr;80(1):81-4. doi: 10.1016/j.lungcan.2012.11.013. Epub 2013 Feb 4.
10
Familial lung adenocarcinoma caused by the EGFR V843I germ-line mutation.由EGFR V843I种系突变引起的家族性肺腺癌。
J Clin Oncol. 2011 Mar 10;29(8):e191-2. doi: 10.1200/JCO.2010.31.4492. Epub 2010 Dec 20.
Zotero 插件